Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes
High baseline levels of interleukin-6 and C-reactive protein confer an increased risk of mortality in non-ST-segment elevation acute coronary syndrome. The aim of the study was to determine whether serial measurements of interleukin-6 and high-sensitivity C-reactive protein provide additional inform...
Gespeichert in:
| Veröffentlicht in: | Revista española de cardiología (English ed.) 2013-03, Vol.66 (3), p.185-192 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 192 |
|---|---|
| container_issue | 3 |
| container_start_page | 185 |
| container_title | Revista española de cardiología (English ed.) |
| container_volume | 66 |
| creator | López-Cuenca, Ángel Manzano-Fernández, Sergio Lip, Gregory Y.H. Casas, Teresa Sánchez-Martínez, Marianela Mateo-Martínez, Alicia Pérez-Berbel, Patricio Martínez, Javier Hernández-Romero, Diana Romero Aniorte, Ana I. Valdés, Mariano Marín, Francisco |
| description | High baseline levels of interleukin-6 and C-reactive protein confer an increased risk of mortality in non-ST-segment elevation acute coronary syndrome. The aim of the study was to determine whether serial measurements of interleukin-6 and high-sensitivity C-reactive protein provide additional information to baseline measurements for risk stratification of non-ST-segment elevation acute coronary syndrome.
Two hundred and sixteen consecutive patients with non-ST-segment elevation acute coronary syndrome were prospectively included. Blood samples were obtained within 24h of hospital admission and at 30 days of follow-up. The endpoint was a composite of all-cause death, nonfatal myocardial infarction, or acute decompensated heart failure.
Both interleukin-6 and high-sensitivity C-reactive protein levels decreased from day 1 to day 30, regardless of adverse events (both P |
| doi_str_mv | 10.1016/j.rec.2012.07.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1520112363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1885585712003386</els_id><sourcerecordid>1520112363</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-4e263465a30881935fca63533a03938a61070bffa6264bc67bbdafc038ac8c323</originalsourceid><addsrcrecordid>eNp9kc1OxCAUhYnR-P8AbgxLN61QCu3ElZmMP4lRE3VNKL1VxhYU6CTzCL61jKPGlSu4Od89gXMQOqIkp4SK03nuQecFoUVOqpzQyQbapXXNM17zavPPfQfthTAnhLO6KrfRTlFWFS95sYs-rm0E38P4amwmsLItvjLPL1kAG0w0CxOXeJp5UDoNgO-9i2As7pzH8WU1Q2uS5Cx2Hb4bo3YDBJyIW2ezh8fk8zyAjXjWw0J9ced6jICnzjur_BI_LG3rV0sHaKtTfYDD73MfPV3MHqdX2c3d5fX0_CbTjLOYlVAIVgquGKlrOmG800okhSnCJqxWgpKKNF2nRCHKRouqaVrVaZIkXWtWsH10svZ98-59hBDlYIKGvlcW3Bgk5SlQWjDBEkrXqPYuBA-dfPNmSK-WlMhVA3IuUwNy1YAklUwNpJ3jb_uxGaD93fiJPAFnawDSJxcGvAzagNUpyOQVZevMP_afTF-Xvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1520112363</pqid></control><display><type>article</type><title>Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>López-Cuenca, Ángel ; Manzano-Fernández, Sergio ; Lip, Gregory Y.H. ; Casas, Teresa ; Sánchez-Martínez, Marianela ; Mateo-Martínez, Alicia ; Pérez-Berbel, Patricio ; Martínez, Javier ; Hernández-Romero, Diana ; Romero Aniorte, Ana I. ; Valdés, Mariano ; Marín, Francisco</creator><creatorcontrib>López-Cuenca, Ángel ; Manzano-Fernández, Sergio ; Lip, Gregory Y.H. ; Casas, Teresa ; Sánchez-Martínez, Marianela ; Mateo-Martínez, Alicia ; Pérez-Berbel, Patricio ; Martínez, Javier ; Hernández-Romero, Diana ; Romero Aniorte, Ana I. ; Valdés, Mariano ; Marín, Francisco</creatorcontrib><description>High baseline levels of interleukin-6 and C-reactive protein confer an increased risk of mortality in non-ST-segment elevation acute coronary syndrome. The aim of the study was to determine whether serial measurements of interleukin-6 and high-sensitivity C-reactive protein provide additional information to baseline measurements for risk stratification of non-ST-segment elevation acute coronary syndrome.
Two hundred and sixteen consecutive patients with non-ST-segment elevation acute coronary syndrome were prospectively included. Blood samples were obtained within 24h of hospital admission and at 30 days of follow-up. The endpoint was a composite of all-cause death, nonfatal myocardial infarction, or acute decompensated heart failure.
Both interleukin-6 and high-sensitivity C-reactive protein levels decreased from day 1 to day 30, regardless of adverse events (both P<.001). Interleukin-6 levels at 2 time points (interleukin-6 day 1, per pg/mL; hazard ratio=1.006, 95% confidence interval, 1.002-1.010; P=.002 and interleukin-6 day 30, per pg/mL, hazard ratio=1.047, 95% confidence interval, 1.021-1.075, P<.001) were independent predictors of adverse events, whereas high-sensitivity C-reactive protein day 1 and high-sensitivity C-reactive protein day 30 levels were not. Patients with interleukin-6 day 1≤8.24 pg/mL and interleukin-6 day 30≤4.45 pg/mL had the lowest event rates (4.7%), whereas those with both above the median values had the highest event rates (35%). After addition of interleukin-6 day 30 to the multivariate model, C-index increased from 0.71 (95% confidence interval, 0.63-0.78) to 0.80 (95% confidence interval, 0.72-0.86), P=.042, and net reclassification improvement was 0.39 (95% confidence interval, 0.14-0.64; P=.002).
In this population, both interleukin-6 and high-sensitivity C-reactive protein concentrations decreased after the acute phase. Serial samples of interleukin-6 concentrations improved the prognostic risk stratification of these patients.
Las concentraciones basales de interleucina 6 y proteína C reactiva elevadas comportan un aumento del riesgo de muerte en el síndrome coronario agudo sin elevación del segmento ST. El objetivo del estudio es delucidar si las determinaciones seriadas de interleucina 6 y proteína C reactiva ultrasensible aportan información pronóstica adicional a las determinaciones basales para la estratificación del riesgo a largo plazo de los pacientes con síndrome coronario agudo sin elevación del segmento ST.
Se incluyó prospectivamente en el estudio a 216 pacientes consecutivos con síndrome coronario agudo sin elevación del segmento ST. Se obtuvieron muestras de sangre en un plazo de 24 h tras el ingreso en el hospital y a los 30 días de seguimiento. La variable de valoración principal fue la combinación de muerte por todas las causas, infarto de miocardio no mortal e insuficiencia cardiaca aguda descompensada.
Las concentraciones tanto de interleucina 6 como de proteína C reactiva ultrasensible se redujeron del día 1 al día 30, con independencia de los eventos adversos aparecidos (p < 0,001 en ambos casos). Los valores de interleucina 6 en los dos momentos de valoración (día 1, por pg/ml; hazard ratio = 1,006; intervalo de confianza del 95%, 1,002-1,010; p = 0,002; día 30, por pg/ml; hazard ratio = 1,047; intervalo de confianza del 95%, 1,021-1,075; p < 0,001) fueron predictores independientes de eventos adversos, pero no los de proteína C reactiva ultrasensible del día 1 y el día 30. Los pacientes con interleucina 6 el día 1 ≤ 8,24 pg/ml y el día 30 ≤ 4,45 pg/ml fueron los que presentaron la tasa de eventos adversos más baja (4,7%), mientras que los pacientes con valores superiores a la mediana de ambos parámetros fueron los que tuvieron la tasa de eventos adversos más alta (35%). Después de la adición de la interleucina 6 del día 30 al modelo multivariable, el índice C aumentó de 0,71 (intervalo de confianza del 95%, 0,63-0,78) a 0,80 (intervalo de confianza del 95%, 0,72-0,86; p = 0,042) y la mejora neta de la reclasificación fue de 0,39 (intervalo de confianza del 95%, 0,14-0,64; p = 0,002).
En esta población, tanto la concentración de interleucina 6 como la de proteína C reactiva ultrasensible se reducen tras la fase aguda. La determinación de las concentraciones de interleucina 6 en muestras seriadas mejora la estratificación pronóstica del riesgo en estos pacientes.</description><identifier>ISSN: 1885-5857</identifier><identifier>EISSN: 1885-5857</identifier><identifier>DOI: 10.1016/j.rec.2012.07.019</identifier><identifier>PMID: 24775452</identifier><language>eng</language><publisher>Spain: Elsevier Espana</publisher><subject>Acute Coronary Syndrome - blood ; Acute Coronary Syndrome - physiopathology ; Aged ; C-Reactive Protein - analysis ; Female ; High-sensitivity C-reactive protein ; Humans ; Interleucina 6 ; Interleukin-6 ; Interleukin-6 - blood ; Male ; Middle Aged ; Non-ST-segment acute coronary syndrome ; Prognosis ; Prospective Studies ; Proteína C reactiva ultrasensible ; Risk Assessment ; Síndrome coronario agudo sin elevación del segmento ST</subject><ispartof>Revista española de cardiología (English ed.), 2013-03, Vol.66 (3), p.185-192</ispartof><rights>2012 Sociedad Española de Cardiología</rights><rights>Copyright © 2012 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-4e263465a30881935fca63533a03938a61070bffa6264bc67bbdafc038ac8c323</citedby><cites>FETCH-LOGICAL-c353t-4e263465a30881935fca63533a03938a61070bffa6264bc67bbdafc038ac8c323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.rec.2012.07.019$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24775452$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>López-Cuenca, Ángel</creatorcontrib><creatorcontrib>Manzano-Fernández, Sergio</creatorcontrib><creatorcontrib>Lip, Gregory Y.H.</creatorcontrib><creatorcontrib>Casas, Teresa</creatorcontrib><creatorcontrib>Sánchez-Martínez, Marianela</creatorcontrib><creatorcontrib>Mateo-Martínez, Alicia</creatorcontrib><creatorcontrib>Pérez-Berbel, Patricio</creatorcontrib><creatorcontrib>Martínez, Javier</creatorcontrib><creatorcontrib>Hernández-Romero, Diana</creatorcontrib><creatorcontrib>Romero Aniorte, Ana I.</creatorcontrib><creatorcontrib>Valdés, Mariano</creatorcontrib><creatorcontrib>Marín, Francisco</creatorcontrib><title>Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes</title><title>Revista española de cardiología (English ed.)</title><addtitle>Rev Esp Cardiol (Engl Ed)</addtitle><description>High baseline levels of interleukin-6 and C-reactive protein confer an increased risk of mortality in non-ST-segment elevation acute coronary syndrome. The aim of the study was to determine whether serial measurements of interleukin-6 and high-sensitivity C-reactive protein provide additional information to baseline measurements for risk stratification of non-ST-segment elevation acute coronary syndrome.
Two hundred and sixteen consecutive patients with non-ST-segment elevation acute coronary syndrome were prospectively included. Blood samples were obtained within 24h of hospital admission and at 30 days of follow-up. The endpoint was a composite of all-cause death, nonfatal myocardial infarction, or acute decompensated heart failure.
Both interleukin-6 and high-sensitivity C-reactive protein levels decreased from day 1 to day 30, regardless of adverse events (both P<.001). Interleukin-6 levels at 2 time points (interleukin-6 day 1, per pg/mL; hazard ratio=1.006, 95% confidence interval, 1.002-1.010; P=.002 and interleukin-6 day 30, per pg/mL, hazard ratio=1.047, 95% confidence interval, 1.021-1.075, P<.001) were independent predictors of adverse events, whereas high-sensitivity C-reactive protein day 1 and high-sensitivity C-reactive protein day 30 levels were not. Patients with interleukin-6 day 1≤8.24 pg/mL and interleukin-6 day 30≤4.45 pg/mL had the lowest event rates (4.7%), whereas those with both above the median values had the highest event rates (35%). After addition of interleukin-6 day 30 to the multivariate model, C-index increased from 0.71 (95% confidence interval, 0.63-0.78) to 0.80 (95% confidence interval, 0.72-0.86), P=.042, and net reclassification improvement was 0.39 (95% confidence interval, 0.14-0.64; P=.002).
In this population, both interleukin-6 and high-sensitivity C-reactive protein concentrations decreased after the acute phase. Serial samples of interleukin-6 concentrations improved the prognostic risk stratification of these patients.
Las concentraciones basales de interleucina 6 y proteína C reactiva elevadas comportan un aumento del riesgo de muerte en el síndrome coronario agudo sin elevación del segmento ST. El objetivo del estudio es delucidar si las determinaciones seriadas de interleucina 6 y proteína C reactiva ultrasensible aportan información pronóstica adicional a las determinaciones basales para la estratificación del riesgo a largo plazo de los pacientes con síndrome coronario agudo sin elevación del segmento ST.
Se incluyó prospectivamente en el estudio a 216 pacientes consecutivos con síndrome coronario agudo sin elevación del segmento ST. Se obtuvieron muestras de sangre en un plazo de 24 h tras el ingreso en el hospital y a los 30 días de seguimiento. La variable de valoración principal fue la combinación de muerte por todas las causas, infarto de miocardio no mortal e insuficiencia cardiaca aguda descompensada.
Las concentraciones tanto de interleucina 6 como de proteína C reactiva ultrasensible se redujeron del día 1 al día 30, con independencia de los eventos adversos aparecidos (p < 0,001 en ambos casos). Los valores de interleucina 6 en los dos momentos de valoración (día 1, por pg/ml; hazard ratio = 1,006; intervalo de confianza del 95%, 1,002-1,010; p = 0,002; día 30, por pg/ml; hazard ratio = 1,047; intervalo de confianza del 95%, 1,021-1,075; p < 0,001) fueron predictores independientes de eventos adversos, pero no los de proteína C reactiva ultrasensible del día 1 y el día 30. Los pacientes con interleucina 6 el día 1 ≤ 8,24 pg/ml y el día 30 ≤ 4,45 pg/ml fueron los que presentaron la tasa de eventos adversos más baja (4,7%), mientras que los pacientes con valores superiores a la mediana de ambos parámetros fueron los que tuvieron la tasa de eventos adversos más alta (35%). Después de la adición de la interleucina 6 del día 30 al modelo multivariable, el índice C aumentó de 0,71 (intervalo de confianza del 95%, 0,63-0,78) a 0,80 (intervalo de confianza del 95%, 0,72-0,86; p = 0,042) y la mejora neta de la reclasificación fue de 0,39 (intervalo de confianza del 95%, 0,14-0,64; p = 0,002).
En esta población, tanto la concentración de interleucina 6 como la de proteína C reactiva ultrasensible se reducen tras la fase aguda. La determinación de las concentraciones de interleucina 6 en muestras seriadas mejora la estratificación pronóstica del riesgo en estos pacientes.</description><subject>Acute Coronary Syndrome - blood</subject><subject>Acute Coronary Syndrome - physiopathology</subject><subject>Aged</subject><subject>C-Reactive Protein - analysis</subject><subject>Female</subject><subject>High-sensitivity C-reactive protein</subject><subject>Humans</subject><subject>Interleucina 6</subject><subject>Interleukin-6</subject><subject>Interleukin-6 - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Non-ST-segment acute coronary syndrome</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Proteína C reactiva ultrasensible</subject><subject>Risk Assessment</subject><subject>Síndrome coronario agudo sin elevación del segmento ST</subject><issn>1885-5857</issn><issn>1885-5857</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1OxCAUhYnR-P8AbgxLN61QCu3ElZmMP4lRE3VNKL1VxhYU6CTzCL61jKPGlSu4Od89gXMQOqIkp4SK03nuQecFoUVOqpzQyQbapXXNM17zavPPfQfthTAnhLO6KrfRTlFWFS95sYs-rm0E38P4amwmsLItvjLPL1kAG0w0CxOXeJp5UDoNgO-9i2As7pzH8WU1Q2uS5Cx2Hb4bo3YDBJyIW2ezh8fk8zyAjXjWw0J9ced6jICnzjur_BI_LG3rV0sHaKtTfYDD73MfPV3MHqdX2c3d5fX0_CbTjLOYlVAIVgquGKlrOmG800okhSnCJqxWgpKKNF2nRCHKRouqaVrVaZIkXWtWsH10svZ98-59hBDlYIKGvlcW3Bgk5SlQWjDBEkrXqPYuBA-dfPNmSK-WlMhVA3IuUwNy1YAklUwNpJ3jb_uxGaD93fiJPAFnawDSJxcGvAzagNUpyOQVZevMP_afTF-Xvw</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>López-Cuenca, Ángel</creator><creator>Manzano-Fernández, Sergio</creator><creator>Lip, Gregory Y.H.</creator><creator>Casas, Teresa</creator><creator>Sánchez-Martínez, Marianela</creator><creator>Mateo-Martínez, Alicia</creator><creator>Pérez-Berbel, Patricio</creator><creator>Martínez, Javier</creator><creator>Hernández-Romero, Diana</creator><creator>Romero Aniorte, Ana I.</creator><creator>Valdés, Mariano</creator><creator>Marín, Francisco</creator><general>Elsevier Espana</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes</title><author>López-Cuenca, Ángel ; Manzano-Fernández, Sergio ; Lip, Gregory Y.H. ; Casas, Teresa ; Sánchez-Martínez, Marianela ; Mateo-Martínez, Alicia ; Pérez-Berbel, Patricio ; Martínez, Javier ; Hernández-Romero, Diana ; Romero Aniorte, Ana I. ; Valdés, Mariano ; Marín, Francisco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-4e263465a30881935fca63533a03938a61070bffa6264bc67bbdafc038ac8c323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acute Coronary Syndrome - blood</topic><topic>Acute Coronary Syndrome - physiopathology</topic><topic>Aged</topic><topic>C-Reactive Protein - analysis</topic><topic>Female</topic><topic>High-sensitivity C-reactive protein</topic><topic>Humans</topic><topic>Interleucina 6</topic><topic>Interleukin-6</topic><topic>Interleukin-6 - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Non-ST-segment acute coronary syndrome</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Proteína C reactiva ultrasensible</topic><topic>Risk Assessment</topic><topic>Síndrome coronario agudo sin elevación del segmento ST</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>López-Cuenca, Ángel</creatorcontrib><creatorcontrib>Manzano-Fernández, Sergio</creatorcontrib><creatorcontrib>Lip, Gregory Y.H.</creatorcontrib><creatorcontrib>Casas, Teresa</creatorcontrib><creatorcontrib>Sánchez-Martínez, Marianela</creatorcontrib><creatorcontrib>Mateo-Martínez, Alicia</creatorcontrib><creatorcontrib>Pérez-Berbel, Patricio</creatorcontrib><creatorcontrib>Martínez, Javier</creatorcontrib><creatorcontrib>Hernández-Romero, Diana</creatorcontrib><creatorcontrib>Romero Aniorte, Ana I.</creatorcontrib><creatorcontrib>Valdés, Mariano</creatorcontrib><creatorcontrib>Marín, Francisco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista española de cardiología (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>López-Cuenca, Ángel</au><au>Manzano-Fernández, Sergio</au><au>Lip, Gregory Y.H.</au><au>Casas, Teresa</au><au>Sánchez-Martínez, Marianela</au><au>Mateo-Martínez, Alicia</au><au>Pérez-Berbel, Patricio</au><au>Martínez, Javier</au><au>Hernández-Romero, Diana</au><au>Romero Aniorte, Ana I.</au><au>Valdés, Mariano</au><au>Marín, Francisco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes</atitle><jtitle>Revista española de cardiología (English ed.)</jtitle><addtitle>Rev Esp Cardiol (Engl Ed)</addtitle><date>2013-03</date><risdate>2013</risdate><volume>66</volume><issue>3</issue><spage>185</spage><epage>192</epage><pages>185-192</pages><issn>1885-5857</issn><eissn>1885-5857</eissn><abstract>High baseline levels of interleukin-6 and C-reactive protein confer an increased risk of mortality in non-ST-segment elevation acute coronary syndrome. The aim of the study was to determine whether serial measurements of interleukin-6 and high-sensitivity C-reactive protein provide additional information to baseline measurements for risk stratification of non-ST-segment elevation acute coronary syndrome.
Two hundred and sixteen consecutive patients with non-ST-segment elevation acute coronary syndrome were prospectively included. Blood samples were obtained within 24h of hospital admission and at 30 days of follow-up. The endpoint was a composite of all-cause death, nonfatal myocardial infarction, or acute decompensated heart failure.
Both interleukin-6 and high-sensitivity C-reactive protein levels decreased from day 1 to day 30, regardless of adverse events (both P<.001). Interleukin-6 levels at 2 time points (interleukin-6 day 1, per pg/mL; hazard ratio=1.006, 95% confidence interval, 1.002-1.010; P=.002 and interleukin-6 day 30, per pg/mL, hazard ratio=1.047, 95% confidence interval, 1.021-1.075, P<.001) were independent predictors of adverse events, whereas high-sensitivity C-reactive protein day 1 and high-sensitivity C-reactive protein day 30 levels were not. Patients with interleukin-6 day 1≤8.24 pg/mL and interleukin-6 day 30≤4.45 pg/mL had the lowest event rates (4.7%), whereas those with both above the median values had the highest event rates (35%). After addition of interleukin-6 day 30 to the multivariate model, C-index increased from 0.71 (95% confidence interval, 0.63-0.78) to 0.80 (95% confidence interval, 0.72-0.86), P=.042, and net reclassification improvement was 0.39 (95% confidence interval, 0.14-0.64; P=.002).
In this population, both interleukin-6 and high-sensitivity C-reactive protein concentrations decreased after the acute phase. Serial samples of interleukin-6 concentrations improved the prognostic risk stratification of these patients.
Las concentraciones basales de interleucina 6 y proteína C reactiva elevadas comportan un aumento del riesgo de muerte en el síndrome coronario agudo sin elevación del segmento ST. El objetivo del estudio es delucidar si las determinaciones seriadas de interleucina 6 y proteína C reactiva ultrasensible aportan información pronóstica adicional a las determinaciones basales para la estratificación del riesgo a largo plazo de los pacientes con síndrome coronario agudo sin elevación del segmento ST.
Se incluyó prospectivamente en el estudio a 216 pacientes consecutivos con síndrome coronario agudo sin elevación del segmento ST. Se obtuvieron muestras de sangre en un plazo de 24 h tras el ingreso en el hospital y a los 30 días de seguimiento. La variable de valoración principal fue la combinación de muerte por todas las causas, infarto de miocardio no mortal e insuficiencia cardiaca aguda descompensada.
Las concentraciones tanto de interleucina 6 como de proteína C reactiva ultrasensible se redujeron del día 1 al día 30, con independencia de los eventos adversos aparecidos (p < 0,001 en ambos casos). Los valores de interleucina 6 en los dos momentos de valoración (día 1, por pg/ml; hazard ratio = 1,006; intervalo de confianza del 95%, 1,002-1,010; p = 0,002; día 30, por pg/ml; hazard ratio = 1,047; intervalo de confianza del 95%, 1,021-1,075; p < 0,001) fueron predictores independientes de eventos adversos, pero no los de proteína C reactiva ultrasensible del día 1 y el día 30. Los pacientes con interleucina 6 el día 1 ≤ 8,24 pg/ml y el día 30 ≤ 4,45 pg/ml fueron los que presentaron la tasa de eventos adversos más baja (4,7%), mientras que los pacientes con valores superiores a la mediana de ambos parámetros fueron los que tuvieron la tasa de eventos adversos más alta (35%). Después de la adición de la interleucina 6 del día 30 al modelo multivariable, el índice C aumentó de 0,71 (intervalo de confianza del 95%, 0,63-0,78) a 0,80 (intervalo de confianza del 95%, 0,72-0,86; p = 0,042) y la mejora neta de la reclasificación fue de 0,39 (intervalo de confianza del 95%, 0,14-0,64; p = 0,002).
En esta población, tanto la concentración de interleucina 6 como la de proteína C reactiva ultrasensible se reducen tras la fase aguda. La determinación de las concentraciones de interleucina 6 en muestras seriadas mejora la estratificación pronóstica del riesgo en estos pacientes.</abstract><cop>Spain</cop><pub>Elsevier Espana</pub><pmid>24775452</pmid><doi>10.1016/j.rec.2012.07.019</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1885-5857 |
| ispartof | Revista española de cardiología (English ed.), 2013-03, Vol.66 (3), p.185-192 |
| issn | 1885-5857 1885-5857 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1520112363 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
| subjects | Acute Coronary Syndrome - blood Acute Coronary Syndrome - physiopathology Aged C-Reactive Protein - analysis Female High-sensitivity C-reactive protein Humans Interleucina 6 Interleukin-6 Interleukin-6 - blood Male Middle Aged Non-ST-segment acute coronary syndrome Prognosis Prospective Studies Proteína C reactiva ultrasensible Risk Assessment Síndrome coronario agudo sin elevación del segmento ST |
| title | Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T07%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-6%20and%20High-sensitivity%20C-reactive%20Protein%20for%20the%20Prediction%20of%20Outcomes%20in%20Non-ST-segment%20Elevation%20Acute%20Coronary%20Syndromes&rft.jtitle=Revista%20espa%C3%B1ola%20de%20cardiolog%C3%ADa%20(English%20ed.)&rft.au=L%C3%B3pez-Cuenca,%20%C3%81ngel&rft.date=2013-03&rft.volume=66&rft.issue=3&rft.spage=185&rft.epage=192&rft.pages=185-192&rft.issn=1885-5857&rft.eissn=1885-5857&rft_id=info:doi/10.1016/j.rec.2012.07.019&rft_dat=%3Cproquest_cross%3E1520112363%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1520112363&rft_id=info:pmid/24775452&rft_els_id=S1885585712003386&rfr_iscdi=true |